Lotus Pharmaceutical Co Stock Shares Owned By Institutions
| 1795 Stock | TWD 281.50 4.00 1.40% |
Lotus Pharmaceutical Co fundamentals help investors to digest information that contributes to Lotus Pharmaceutical's financial success or failures. It also enables traders to predict the movement of Lotus Stock. The fundamental analysis module provides a way to measure Lotus Pharmaceutical's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Lotus Pharmaceutical stock.
Lotus |
Lotus Pharmaceutical Co Company Shares Owned By Institutions Analysis
Lotus Pharmaceutical's Shares Owned by Institutions show the percentage of the outstanding shares of stock issued by a company that is currently owned by other institutions such as asset management firms, hedge funds, or investment banks. Many investors like investing in companies with a large percentage of the firm owned by institutions because they believe that larger firms such as banks, pension funds, and mutual funds, will invest when they think that good things are going to happen.
More About Shares Owned By Institutions | All Equity Analysis
Shares Held by Institutions | = | Funds and Banks | + | Firms |
Current Lotus Pharmaceutical Shares Owned By Institutions | 10.54 % |
Most of Lotus Pharmaceutical's fundamental indicators, such as Shares Owned By Institutions, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Lotus Pharmaceutical Co is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Since Institution investors conduct a lot of independent research they tend to be more involved and usually more knowledgeable about entities they invest as compared to amateur investors.
| Competition |
Based on the latest financial disclosure, 10.54% of Lotus Pharmaceutical Co are shares owned by institutions. This is 76.39% lower than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—Specialty & Generic industry. The shares owned by institutions for all Taiwan stocks is 73.12% higher than that of the company.
Lotus Shares Owned By Institutions Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Lotus Pharmaceutical's direct or indirect competition against its Shares Owned By Institutions to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Lotus Pharmaceutical could also be used in its relative valuation, which is a method of valuing Lotus Pharmaceutical by comparing valuation metrics of similar companies.Lotus Pharmaceutical is number one stock in shares owned by institutions category among its peers.
Lotus Fundamentals
| Return On Equity | 0.26 | |||
| Return On Asset | 0.11 | |||
| Profit Margin | 0.22 % | |||
| Operating Margin | 0.31 % | |||
| Current Valuation | 73.53 B | |||
| Shares Outstanding | 262.04 M | |||
| Shares Owned By Insiders | 61.63 % | |||
| Shares Owned By Institutions | 10.54 % | |||
| Price To Earning | 16.94 X | |||
| Price To Book | 4.97 X | |||
| Price To Sales | 4.31 X | |||
| Revenue | 12.65 B | |||
| Gross Profit | 5.64 B | |||
| EBITDA | 2.93 B | |||
| Net Income | 1.4 B | |||
| Cash And Equivalents | 1.97 B | |||
| Cash Per Share | 8.02 X | |||
| Total Debt | 4.67 B | |||
| Debt To Equity | 0.82 % | |||
| Current Ratio | 1.93 X | |||
| Book Value Per Share | 51.30 X | |||
| Cash Flow From Operations | 119.66 M | |||
| Earnings Per Share | 11.86 X | |||
| Target Price | 297.67 | |||
| Number Of Employees | 10 | |||
| Beta | 0.72 | |||
| Market Capitalization | 70.1 B | |||
| Total Asset | 21.22 B | |||
| Z Score | 9.0 | |||
| Annual Yield | 0.01 % | |||
| Net Asset | 21.22 B | |||
| Last Dividend Paid | 1.93 |
About Lotus Pharmaceutical Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Lotus Pharmaceutical Co's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Lotus Pharmaceutical using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Lotus Pharmaceutical Co based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Lotus Stock Analysis
When running Lotus Pharmaceutical's price analysis, check to measure Lotus Pharmaceutical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lotus Pharmaceutical is operating at the current time. Most of Lotus Pharmaceutical's value examination focuses on studying past and present price action to predict the probability of Lotus Pharmaceutical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lotus Pharmaceutical's price. Additionally, you may evaluate how the addition of Lotus Pharmaceutical to your portfolios can decrease your overall portfolio volatility.